UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 18 Source: CRO
- €36.9 million turnover
-
€25.8 million
profit - 1 employees
-
31st Dec 17 Source: CRO
- €163 million turnover
-
€12.2 million
profit - 1 employees
- 10 more years available »
Ranking
By Turnover
(€36.9 million)- 764th in Top Companies
- 89th in Health
- 77th in Pharma
By Employees
(1)- 990th in Top Companies
- 97th in Health
- 84th in Pharma
-
- 1
- €36.9 million
Employees
- Steve Turley CEO/Managing Director
Latest News
- 12:13am Air New Zealand to lay off 3,500 staff as coronavirus stunts travel
- Mar 30 Digicel gets 30-day grace period for interest payments on $2.9bn of debt
- Mar 30 NY’s largest healthcare provider using Irish technology in Covid-19 testing
- Mar 30 New York’s largest healthcare provider using Irish tech to break down test waste
- Mar 30 Shares edge higher as relative calm reigns over markets